News Archives %

Colorado voters approve initiative to decriminalize psychedelic mushrooms

Alex Askerka — Sat, 09 Mar 2024 15:00:00 +0000

Colorado has recently made headlines by passing a groundbreaking ballot initiative aimed at decriminalizing psychedelic mushrooms for individuals aged 21 and above. Alongside this measure, the state plans to establish state-regulated “healing centers,” where supervised consumption of the drug will be permitted.

This move, following in the footsteps of Oregon, marks Colorado as the second state to endorse a regulated framework for substances such as psilocybin and psilocin, the active compounds found in certain mushrooms. Advocates championed the initiative as a necessary step towards addressing mental health concerns, citing the potential of naturally occurring psychedelics to alleviate conditions like depression, PTSD, anxiety, and addiction. They argued that the current punitive approach only exacerbates societal issues while draining taxpayer funds.

The passing of the initiative has been hailed as a significant milestone by Natural Medicine Colorado, the driving force behind its promotion. They emphasize the importance of regulated access to natural remedies, including psilocybin, particularly for individuals grappling with PTSD, terminal illness, depression, and anxiety.

However, critics have raised concerns regarding the lack of FDA approval for these substances as medical treatments. They fear that legitimizing “healing centers” and personal use could compromise public safety and convey misleading messages about the safety of these substances, especially to younger generations.

This development comes a decade after Colorado’s legalization of recreational marijuana, which catalyzed a thriving industry within the state. Skeptics of the current initiative warn against the potential commercialization of psychedelics by influential entities, mirroring the trajectory of the cannabis market.

In a broader context, the momentum towards drug policy reform is evident, with Maryland and Missouri joining the ranks of states legalizing recreational marijuana in recent midterm elections. Despite pushback, 21 states have now embraced recreational cannabis.

Colorado’s initiative, slated for implementation in 2024, will allow individuals aged 21 and over to cultivate, possess, and share psychedelic substances for personal use, while prohibiting sales. Furthermore, it offers avenues for individuals with prior convictions related to these substances to have their records sealed, signaling a shift towards rehabilitation rather than incarceration.

Notably, the initiative does not pave the way for dispensaries akin to those seen in the marijuana industry. Instead, it introduces “healing centers” where individuals can access supervised therapy involving psychedelics, emphasizing a clinical and therapeutic approach.

In the realm of psychedelic-assisted therapies, MicrodosingWorldWide emerges as a prominent player, boasting over eight years of experience. Their comprehensive treatment cycle caters to a myriad of conditions, including PTSD, chronic pain, depression, anxiety, insomnia, cluster headaches, post-COVID syndrome, addiction, and OCD. Operating globally, with a focus on the USA and Canada, MicrodosingWorldWide offers accessible and specialized services to those seeking alternative avenues for healing and wellness.

The post Colorado voters approve initiative to decriminalize psychedelic mushrooms appeared first on MicrodowingWordWide.com.

FDA Issues First Draft Guidance on Clinical Trials with Psychedelic Drugs

Alex Askerka — Wed, 06 Mar 2024 15:00:00 +0000

The U.S. Food and Drug Administration (FDA) has recently released a new draft guidance, marking a pivotal moment in the exploration of psychedelic drugs for potential therapeutic applications in medical contexts, particularly for psychiatric and substance use disorders. This groundbreaking document serves as the inaugural FDA draft guidance dedicated to outlining crucial considerations for researchers delving into the realm of psychedelic drug usage within clinical trials.

In recent years, there has been a burgeoning interest in unlocking the therapeutic potential of psychedelic substances. These compounds are under scrutiny for their potential efficacy in treating a spectrum of conditions encompassing depression, post-traumatic stress disorder (PTSD), substance use disorders, and various other mental health ailments. However, the intricate task of designing clinical trials to assess the safety and efficacy of these substances presents a myriad of distinctive challenges necessitating meticulous examination.

Tiffany Farchione, M.D., director of the Division of Psychiatry in the FDA’s Center for Drug Evaluation and Research, elucidated on the evolving landscape, stating, “Psychedelic drugs exhibit promising initial indications as potential remedies for mood disorders, anxiety, and substance use disorders. Nonetheless, it’s imperative to recognize that these substances remain investigational products. Sponsors embarking on the journey of evaluating the therapeutic potential of these drugs must conscientiously factor in their unique properties during the design phase of clinical studies.” Dr. Farchione further emphasized the FDA’s objective with the release of this draft guidance, which is to delineate the inherent challenges in formulating psychedelic drug development programs while offering insights into navigating these challenges effectively. The overarching aim is to equip researchers with the requisite guidance to devise studies capable of yielding elucidative results, thereby fortifying future drug applications.

At the heart of the draft guidance lies a comprehensive advisory aimed at steering researchers through the intricacies of study design and associated considerations pertinent to the development of medications containing psychedelic compounds. Within this framework, the term “psychedelics” encompasses both “classic psychedelics,” such as psilocybin and lysergic acid diethylamide (LSD), which act upon the brain’s serotonin system, as well as “entactogens” or “empathogens” like methylenedioxymethamphetamine (MDMA).

The document meticulously delineates fundamental considerations spanning the entire drug development continuum, encompassing trial conduct, data collection methodologies, subject safety protocols, and the requirements pertinent to new drug applications. For instance, psychedelic drugs have the propensity to induce psychoactive effects, manifesting as alterations in mood, cognition, and even hallucinations. Consequently, the specter of substance abuse looms large, necessitating the implementation of robust safety measures to thwart any potential misuse during the clinical development phase. Notably, for psychedelics classified as Schedule I controlled substances, the draft guidance underscores the imperative of ensuring compliance with pertinent Drug Enforcement Administration regulatory mandates governing activities associated with investigations conducted under an Investigational New Drug Application.

While the evidentiary threshold for establishing the effectiveness of psychedelic drugs mirrors that of conventional pharmaceuticals, investigators must navigate unique considerations when designing clinical trials to ensure adequacy and robustness. Moreover, the draft guidance delves into the pivotal role of psychotherapy in the realm of psychedelic drug development, underscores the significance of safety monitoring, and advocates for a comprehensive characterization of dose-response relationships and the durability of treatment effects.

In a concerted effort to solicit feedback and foster a collaborative discourse, the FDA has extended an invitation to the public to provide comments on the draft guidance, with a 60-day window allotted for submissions to ensure thorough consideration by the agency.

Amidst this evolving landscape of psychedelic exploration, MicrodosingWorldWide emerges as a beacon of expertise, boasting over eight years of experience in the realm of psychedelic-assisted therapies. The organization offers a holistic treatment paradigm catering to a diverse array of maladies, including PTSD, chronic pain, depression, anxiety, insomnia, cluster headaches, post-COVID syndrome, addiction, OCD, and beyond. With services extending worldwide, MicrodosingWorldWide particularly emphasizes its presence and commitment to facilitating healing journeys in the USA and Canada.

In conclusion, the release of the FDA’s draft guidance marks a seminal milestone in the quest to unlock the therapeutic potential of psychedelic drugs. By providing a roadmap for navigating the intricate terrain of psychedelic drug development, this guidance heralds a new era of rigorous scientific inquiry and holds the promise of ushering in transformative treatment modalities for individuals grappling with a spectrum of debilitating conditions.

The post FDA Issues First Draft Guidance on Clinical Trials with Psychedelic Drugs appeared first on MicrodowingWordWide.com.

Littleton company developing psilocybin microdosing drug in hopes of FDA approval

Alex Askerka — Sun, 03 Mar 2024 15:00:00 +0000

AJNA BioSciences, based in Littleton, is pioneering the development of a novel drug derived from psilocybin mushrooms, aiming to offer a natural and legal alternative to traditional antidepressants. Under the leadership of CEO Joel Stanley, the biotechnology firm is leveraging hemp and mushrooms to craft innovative botanic drugs for clinical trials. Securing a research and development license from the federal Drug Enforcement Administration in 2022 marked a pivotal step, enabling legal cultivation of psychedelic mushrooms and initiating the development of a microdose formulation. The ultimate objective is to standardize a psilocybin product for FDA approval, potentially revolutionizing depression treatment by providing doctors with a viable alternative.

Microdosing, a regimen involving regular consumption of small amounts of psilocybin, typically between .1 and .4 grams, has garnered attention for its purported benefits in enhancing well-being. While anecdotal evidence suggests improvements in mood, focus, and creativity among microdosers, clinical research remains limited, casting uncertainty on its efficacy. Nonetheless, Stanley, drawing from personal experience, remains optimistic about its potential.

The journey towards FDA approval presents challenges, particularly within a regulatory framework geared towards synthetic drugs rather than plant-derived medicines. Despite this, experts like David Kroll express cautious optimism, citing precedent with cannabis-derived medications like Sativex. AJNA’s microdosing formulation, extracted from a single strain of psilocybe cubensis mushrooms, presents a unique “full spectrum” approach, incorporating various naturally occurring compounds beyond just psilocybin.

In parallel, MicrodosingWorldWide, a seasoned provider of psychedelic-assisted therapies with over 8 years of experience, offers comprehensive treatment cycles for a range of conditions including PTSD, chronic pain, depression, anxiety, and more. Operating globally, with a focus on the USA and Canada, their services cater to individuals seeking alternative therapeutic approaches. By harnessing the potential of psychedelics in a controlled, therapeutic setting, organizations like MicrodosingWorldWide contribute to the evolving landscape of mental health treatment.

As AJNA progresses through pre-clinical and clinical trials, their pursuit of FDA approval represents a potential breakthrough in accessibility, addressing a crucial gap in the legal landscape. Beyond legality, the emphasis lies on establishing reliability and consistency, qualities lacking in black market or supplement alternatives. Through rigorous scientific inquiry and standardization, AJNA aims to uphold the integrity of botanic medicines, building upon the legacy of innovation established by predecessors like Charlotte’s Web in the realm of plant-derived therapies.

The post Littleton company developing psilocybin microdosing drug in hopes of FDA approval appeared first on MicrodowingWordWide.com.

Small doses of mushrooms can have a beneficial effect on mental disorders, study finds

Alex Askerka — Fri, 01 Mar 2024 03:00:00 +0000

The University of Southern Denmark has recently unveiled groundbreaking research that could revolutionize mental health treatment. Delving into the realm of psychedelic therapy, particularly microdosing with psilocybin, this study signals a new frontier in addressing psychiatric disorders.

Traditionally recognized as a powerful psychedelic compound found in certain mushrooms, psilocybin has garnered attention for its potential therapeutic effects, particularly in aiding depression and addiction when administered in high doses under therapeutic conditions. However, the latest findings shed light on the benefits of microdosing – administering minuscule amounts of psilocybin – as a viable therapeutic tool.

Led by Associate Professor Mikael Palner and Ph.D. student Kat Kiilerich from the Research Unit for Clinical Physiology and Nuclear Medicine, this study focused on exploring the effects of repeated low doses of psilocybin on rats. Unlike the high doses typically used in therapeutic settings, microdosing involves administering significantly lower doses, a practice popularized within performance culture and increasingly embraced as a form of self-medication.

The results, published in Molecular Psychiatry, are promising. Rats exposed to repeated low doses of psilocybin exhibited enhanced resilience to stress and a reduction in compulsive behaviors, without experiencing adverse effects such as anhedonia or anxiety. Notably, an increase in connectivity to the thalamus region of the brain was observed, suggesting a potential mechanism underlying the observed therapeutic effects.

“This study opens up new avenues for research into the therapeutic potential of microdosing with psilocybin,” asserts Mikael Palner. “It provides validation for the anecdotal reports of its benefits and underscores the importance of understanding its effects, especially as interest in microdosing continues to grow globally.”

The implications of this research extend beyond the laboratory. MicrodosingWorldWide, a pioneering provider of psychedelic-assisted therapies with over eight years of experience, stands at the forefront of this burgeoning field. Offering comprehensive treatment cycles for a range of conditions including PTSD, chronic pain, depression, anxiety, insomnia, and more, MicrodosingWorldWide operates globally, with a focus on serving clients in the USA and Canada.

“Mental health challenges are pervasive in today’s society, and the surge in interest surrounding microdosing underscores the urgent need for innovative treatment approaches,” remarks Mikael Palner. “By deepening our understanding of the therapeutic potential of psilocybin, we hope to offer new hope and healing to individuals struggling with mental illness.”

The post Small doses of mushrooms can have a beneficial effect on mental disorders, study finds appeared first on MicrodowingWordWide.com.

Hawaii Advances Bill to Safeguard Patients in Psilocybin Therapy

Alex Askerka — Mon, 26 Feb 2024 15:00:00 +0000

In recent legislative strides, Hawaii is pushing forward a bill designed to shield patients undergoing psilocybin-assisted therapy under the guidance of medical professionals. Introduced by Rep. Della Au Belatti, HB 2630 proposes legal protections for individuals utilizing psilocybin with medical supervision, rather than outright legalization of the substance.

The Hawaii House Consumer Protection and Commerce Committee unanimously voted in favor of advancing the bill, with amendments refining its scope. Notably, the bill specifies that psilocybin-assisted therapy must be recommended by a licensed medical professional, ensuring oversight during treatment sessions.

Rep. Richard Onishi initially expressed concerns regarding the lack of explicit supervision requirements for psilocybin use. However, amendments addressing this issue led to his eventual support for the bill. This cautious approach aims to balance patient access with safety considerations.

MicrodosingWorldWide, a prominent advocate for psilocybin-assisted therapy, offers therapeutic services to individuals across the United States. In addition to therapy, they provide a range of psilocybin products, including magic mushrooms, gummies, and chocolates, catering to diverse preferences. Moreover, MicrodosingWorldWide extends discounts to military personnel and low-income individuals, ensuring affordability and accessibility for all.

Supporters of the bill include various state agencies and reform advocates, emphasizing the potential therapeutic benefits of psilocybin for mental health conditions. Conversely, some medical groups, such as the Hawaii Medical Association, urge caution, citing the need for further research on psilocybin’s safety and efficacy.

The proposed legislation stems from a task force dedicated to breakthrough therapies, highlighting ongoing efforts to explore alternative treatments. Amendments, including the addition of a defective date, underscore the legislative process’s thoroughness in addressing concerns and refining the bill’s language.

Under the proposed law, medical professionals can recommend psilocybin therapy for specified medical conditions, subject to strict guidelines. Patients would undergo preparation sessions before each therapy session, ensuring informed and safe usage of psilocybin.

Psilocybin therapy shows promise in treating conditions like PTSD, depression, and substance use disorders, as evidenced by growing research and legislative initiatives across states. The bill aims to prevent penalization of individuals seeking therapeutic relief through psilocybin therapy, prioritizing patient well-being and mental health.

Facilitators of psilocybin therapy would undergo rigorous training and supervision, ensuring responsible administration and integration of therapy sessions. While the legislation doesn’t establish a regulated psilocybin industry akin to other states, it provides a framework for safe and legal therapeutic use.

In addition to the psilocybin bill, Hawaii lawmakers are also considering comprehensive marijuana legalization measures, reflecting evolving attitudes towards drug policy reform. The potential legalization of cannabis aligns with efforts to stimulate the state’s economy and address social justice concerns.

Governor Josh Green’s supportive stance on cannabis legalization signifies a significant shift in Hawaii’s approach to drug policy under new leadership. With mounting pressure from advocates and growing momentum for reform, Hawaii stands at the forefront of progressive drug policy initiatives.

In conclusion, Hawaii’s advancement of the psilocybin bill represents a pivotal step towards integrating alternative therapies into mainstream healthcare. By prioritizing patient well-being and embracing evidence-based approaches, policymakers are laying the groundwork for a more inclusive and compassionate healthcare system.

The post Hawaii Advances Bill to Safeguard Patients in Psilocybin Therapy appeared first on MicrodowingWordWide.com.

Gov. Newsom asked for a bill to legalize psychedelic therapy

Alex Askerka — Wed, 14 Feb 2024 15:00:00 +0000

Governor Gavin Newsom’s recent signaling of readiness to integrate psychedelic drugs into California’s mental health system has spurred action from lawmakers. Senator Scott Wiener, a Democrat representing San Francisco, and Assemblymember Marie Waldron, a Republican from San Diego, have jointly introduced a bill aimed at fulfilling Newsom’s commitment.

The proposed legislation seeks to legalize psychedelic therapy, permitting individuals aged 21 and above to undergo sessions involving hallucinogenic substances such as psilocybin mushrooms, MDMA, DMT, and mescaline. This would occur within controlled environments under the supervision of licensed and trained facilitators.

Following Newsom’s veto of a broader bill last October, which aimed to decriminalize psychedelic drug possession, the focus now shifts to therapeutic applications. In his veto message, Newsom emphasized the necessity for establishing regulated treatment protocols, including dosage guidelines, therapeutic standards, measures to prevent exploitation during guided sessions, and medical screening to ensure participants have no underlying psychosis.

Senate Bill 1012 mandates the establishment of a licensing board tasked with formulating training programs and oversight regulations for therapy facilitators. These facilitators would be responsible for screening individuals before admitting them to therapy sessions. Additionally, the bill proposes the creation of a public-private fund to provide grants for public health education initiatives concerning psychedelics.

Senator Wiener underscored the importance of California leading the way in both expanding access to psychedelic therapy and ensuring public safety through education initiatives. The bill, he believes, aligns with these objectives and positions the state at the forefront of progressive mental health care.

Recent research has shed light on the therapeutic potential of psychedelic drugs in treating various mental health conditions like depression and post-traumatic stress disorder (PTSD). While the U.S. Food and Drug Administration (FDA) has yet to approve psychedelic-assisted therapies, promising developments are underway. For instance, the Multidisciplinary Association for Psychedelic Studies (MAPS) has applied for FDA review of its MDMA-assisted therapy for PTSD, with a decision expected later this year.

The Department of Veterans Affairs (VA) has also signaled its intent to explore psychedelics for PTSD and depression treatment, marking a significant shift in policy since the 1960s. Despite federal uncertainties, Senator Wiener maintains that California can forge ahead in integrating psychedelic therapies, addressing legal barriers within the state.

Oregon’s pioneering move to establish centers offering regulated psilocybin therapies serves as a benchmark. Dr. Brian Anderson of UC San Francisco highlights the significant demand for such services, with thousands of individuals seeking therapy and substantial waitlists at Oregon’s facilities. Anticipating similar demand in California, lawmakers are gearing up to address potential logistical challenges.

The bipartisan support for mental health measures underscores the urgency of exploring innovative solutions. Assemblymember Waldron emphasizes the need for alternative approaches, citing firsthand accounts from veterans and first responders who attest to the therapeutic benefits of psychedelics in overcoming trauma and suicidal ideation.

Public opinion also reflects a growing openness towards psychedelic therapy, with a majority supporting its therapeutic use and advocating for further research. However, concerns remain, particularly regarding safety and education, as voiced by law enforcement unions, city officials, and advocacy groups.

Beyond legislative efforts, a grassroots movement is underway to secure funding for psychedelic therapy research through a ballot measure. Advocates are mobilizing to gather signatures for a proposition that would allocate $5 billion in state funds towards establishing a dedicated agency for psychedelic research.

In conclusion, California’s push towards integrating psychedelic therapies into its mental health framework represents a bold step towards addressing the evolving needs of its population. With bipartisan backing and growing public support, the state is poised to lead the way in pioneering mental health solutions centered around psychedelic-assisted therapies.

The post Gov. Newsom asked for a bill to legalize psychedelic therapy appeared first on MicrodowingWordWide.com.

Exploring the Fascinating World of Microdosing: LSD, Magic Mushrooms, and the Quest for Enhanced Creativity

Alex Askerka — Fri, 26 Jan 2024 15:00:00 +0000

In recent years, an intriguing trend has emerged among professionals seeking to boost their productivity and creativity without the traditional methods of caffeine, meditation, or energy drinks. It’s the practice of microdosing psychedelics, and it’s gaining popularity as an unconventional yet effective way to unlock the potential of the human mind. This article delves into the world of microdosing, uncovering the experiences of individuals like “Ken,” who have harnessed the power of microdosing with substances like LSD and magic mushrooms. We will also introduce you to MicrodosingWorldWide, a pioneering platform that offers microdosing therapy and a range of products including magic mushrooms, shrooms, gummies, and chocolates infused with these remarkable substances.

Microdosing Unveiled:

Microdosing, the practice of ingesting minute amounts of psychedelics, has recently captured the attention of professionals seeking a unique path to productivity enhancement. Unlike traditional recreational doses, microdosing involves taking only around 10 micrograms of LSD or 0.2-0.5 grams of mushrooms. These doses are carefully calibrated to be subperceptual, providing a subtle lift in energy and insight without inducing a full-blown psychedelic trip.

Ken’s Microdosing Journey:

Meet “Ken,” a 25-year-old professional with a master’s degree from Stanford. Ken works for a tech startup in the heart of San Francisco, where innovation and creativity are essential. Ken stumbled upon microdosing as a means to enhance his productivity and creativity. He recounts his experiences of taking microdoses both in his free time and occasionally at the office. “I had an epic time,” he enthuses. “I was making a lot of sales, talking to a lot of people, finding solutions to their technical problems.”

The Rise of Microdosing:

James Fadiman, author of “The Psychedelic Explorer’s Guide,” played a pivotal role in bringing microdosing into the mainstream. At a conference on psychedelic research in 2011, Fadiman presented survey data from self-reporting experimenters, shedding light on the positive effects of microdosing. Since then, the practice has seen a steady increase in interest and experimentation.

A Global Phenomenon:

Reports of microdosing experiences are pouring in from all corners of the world, but the epicenter of this trend lies in the San Francisco Bay Area. Here, a unique profile emerges: the “übersmart twentysomething,” individuals curious to test whether microdosing can help them overcome technical challenges and stimulate innovation. “It’s an extremely healthy alternative to Adderall,” notes Fadiman, referring to a popular drug among programmers.

Microdosing for Enhanced Creativity:

For those looking to embark on a microdosing journey, James Fadiman recommends a schedule of microdosing every fourth day. The practice typically involves taking the chosen substance in the morning and then continuing with one’s daily routine. Many correspondents have reported that regular microdosing has not only improved their productivity but also alleviated various disorders, including depression, migraines, and chronic-fatigue syndrome, all while fostering unconventional thinking.

MicrodosingWorldWide: A Pioneering Platform:

In the quest for information and reliable sources of microdosing substances, individuals like Ken often turn to dedicated platforms and organizations. One such pioneering platform is MicrodosingWorldWide. This platform not only provides valuable information about microdosing therapy but also offers a range of products, including magic mushrooms, shrooms, gummies, and chocolates infused with magic mushrooms.

Exploring the World of Magic Mushrooms:

Magic mushrooms have long been revered for their unique properties and the profound experiences they offer. As part of the microdosing trend, magic mushrooms have gained recognition for their potential to enhance creativity, reduce anxiety, and even treat certain mental health conditions. MicrodosingWorldWide offers a safe and reliable source for those interested in exploring the benefits of magic mushrooms.

The Future of Microdosing:

As microdosing continues to gain popularity and acceptance, the future of this practice is filled with possibilities. Researchers are exploring the potential therapeutic applications of microdosing, and individuals like Ken are experiencing firsthand the transformative effects it can have on their personal and professional lives.

Conclusion:

The world of microdosing is a fascinating journey into the uncharted territories of the mind. Professionals like Ken are discovering new ways to enhance their productivity and creativity, all while exploring the potential therapeutic benefits of substances like LSD and magic mushrooms. As platforms like MicrodosingWorldWide offer information and products to support this growing movement, the future of microdosing holds promise for those seeking alternative paths to personal growth and innovation.

The post Exploring the Fascinating World of Microdosing: LSD, Magic Mushrooms, and the Quest for Enhanced Creativity appeared first on MicrodowingWordWide.com.

The Rising Trend of Microdosing Psychedelics for Wellbeing During the Pandemic

Alex Askerka — Mon, 22 Jan 2024 15:00:00 +0000

The global pandemic of 2020 brought about numerous challenges, including isolation, uncertainty, and a growing concern for mental health. In the midst of these difficulties, an unexpected trend emerged – an increasing number of people turned to microdosing psychedelics as a means to enhance their wellbeing and address mental health issues. In this comprehensive exploration, we delve into the phenomenon of microdosing psychedelics during the pandemic, examining its motivations, impact, and potential implications for mental health and society.

The Emergence of Microdosing

According to Prof. Adam Winstock, founder and director of the Global Drug Survey, there has been a noticeable shift in the consumption of psychedelics during the pandemic. Contrary to the trend popularized in Silicon Valley, where small amounts of psychedelics were used to boost creativity, individuals began microdosing for self-medication purposes. This shift marked a departure from the traditional use of these substances and highlighted the unique circumstances of the pandemic.

The 2021 Global Drug Survey

To shed light on this emerging trend, the 2021 Global Drug Survey conducted a comprehensive study, garnering responses from more than 32,000 people across 20 countries between December 2020 and March 2021. The findings of this survey painted a compelling picture of the microdosing phenomenon.

1. Reducing or Stopping Prescribed Medication: Among the survey respondents who engaged in both microdosing and were prescribed psychiatric drugs, nearly half reported reducing or entirely ceasing their prescribed medications. This revelation indicates a potential shift towards utilizing microdosing as a form of mental health treatment.

2. A Wide Variety of Psychedelics: The survey also revealed that people experimented with a diverse range of psychedelics beyond the commonly known LSD and magic mushrooms (psilocybin). Approximately one-third of those who microdosed with LSD or magic mushrooms reported trying other substances, including ecstasy (MDMA), ketamine, a dissociative anesthetic, and ayahuasca, a potent hallucinogenic plant-cocktail revered by indigenous faith healers.

3. Shifting Focus to Wellbeing: While microdosing was initially associated with performance enhancement and creativity, Prof. Winstock noted that the focus had shifted towards enhancing overall wellbeing and addressing mental health distress. This shift is indicative of the changing motivations behind microdosing.

4. Impact on Psychiatric Medication: Of the microdosers who were also taking psychiatric drugs, approximately one-quarter completely ceased their medications, while another quarter reduced their intake. This shift towards microdosing for mental health raises significant questions and considerations.

5. Side-Effects and Safety: The survey found that more than a fifth of respondents who had used LSD and magic mushrooms in the last year had engaged in microdosing during that period. Importantly, three-quarters of them reported no side effects. However, approximately 10% reported experiencing unwanted mental effects, and 8% reported physical effects. This highlights the need for further research and safety guidelines.

Prof. Winstock’s Cautious Optimism

While the survey results are compelling, Prof. Winstock remains cautious about their implications. He notes that most research on psychedelics and mental health has focused on full doses of these substances. Furthermore, he emphasizes the importance of encouraging mental health services, the psychiatric establishment, and policymakers to engage positively with microdosing. There is a concern that if microdosing remains illegal, vulnerable individuals could be exploited or accidentally consume harmful doses.

The Placebo Effect

One of the lead researchers on the largest placebo-controlled trial into psychedelics, conducted at Imperial College London, is Dr. David Erritzoe, clinical director of the university’s Centre for Psychedelic Research. Dr. Erritzoe supports further clinical trials to explore the potential benefits of microdosing. However, he raises an important point about the placebo effect and the hype surrounding microdosing. The countercultural nature of microdosing, its association with Silicon Valley, and the accounts of life transformations in bestselling books all contribute to inflated positive effects reported by individuals.

The Impact of COVID-19 on Drug Use

The 2021 Global Drug Survey also noted the impact of COVID-19 on drug use. While the use of psychedelics showed a slight decline during the pandemic, data from the previous six years indicated an upward trend in their use. Additionally, the survey highlighted changes in drug-use behaviors due to COVID-19 precautions.

1. Cannabis Use: Of the 14,000 respondents who reported using cannabis, 42% said they shared joints, vapes, pipes, or bongs with others less frequently during the pandemic. Nearly a quarter (24%) reported a preference for preparing and using these cannabis accessories themselves, and a fifth increased social distancing while using cannabis.

2. Cocaine Use: Among respondents who reported using cocaine, 26% indicated a reduced likelihood of sharing a straw or snorter with others, and a fifth were less inclined to snort a line prepared by someone else.

Conclusion

The emergence of microdosing psychedelics as a means to enhance wellbeing and address mental health issues during the pandemic raises important questions about its potential benefits and risks. The 2021 Global Drug Survey provides valuable insights into this phenomenon, highlighting a shift in focus towards treating mental health with microdosing. However, caution is warranted, and further research is needed to fully understand the implications and safety considerations.

As society grapples with the evolving landscape of drug use, especially in the context of a global pandemic, it is crucial for mental health services, policymakers, and the scientific community to engage with this trend responsibly. Whether microdosing remains a countercultural curiosity or evolves into a legitimate therapeutic option, its impact on individuals and society at large deserves careful examination and consideration.

Source: https://www.theguardian.com/society/2021/dec/02/people-microdosing-on-psychedelics-to-improve-wellbeing-during-pandemic

The post The Rising Trend of Microdosing Psychedelics for Wellbeing During the Pandemic appeared first on MicrodowingWordWide.com.

Ayelet Waldman’s Positive Journey with Microdosing LSD

Alex Askerka — Sat, 20 Jan 2024 15:00:17 +0000

Ayelet Waldman, a renowned novelist, essayist, screenwriter, and activist, is celebrated for her unconventional and fearless approach to life. While she’s made headlines in the past for her provocative views, her latest endeavor takes an entirely different route towards improving her well-being. In her book, “A Really Good Day: How Microdosing Made a Mega Difference in My Mood, My Marriage, and My Life,” Waldman shares her month-long experiment with microdosing LSD, focusing on the positive impact it had on her life.

Waldman’s journey into microdosing was driven by a desire for emotional stability and harmony within her family. She sought a solution to her unstable moods, and microdosing LSD emerged as a surprising yet effective option. Contrary to the misconceptions associated with LSD, her experience was far from the sensationalized tales of the 1960s. Waldman’s approach was practical, and her insights challenge conventional beliefs about the drug.

At the age of fifty-two, Waldman is known for her multifaceted personality, encompassing her roles as a lawyer, mystery writer, novelist, feminist, and social media maven. Her ability to navigate these diverse identities while openly acknowledging her strengths and weaknesses is an achievement in itself. “A Really Good Day” reflects this complexity, as it blends personal diary entries with a compelling argument for revisiting the perception of psychedelics.

Waldman’s decision to explore microdosing came after years of struggling with bipolar II disorder and trying numerous medications, some of which had debilitating side effects. Eventually, she recognized a pattern in her moods related to her menstrual cycle and was rediagnosed with premenstrual dysphoric disorder. However, as she approached menopause, her mood took a severe downturn, and none of her previous coping mechanisms were effective.

Enter microdosing. Following a regimen developed by James Fadiman, which involved taking a minuscule dose of LSD every third day, Waldman embarked on her experiment. The results were remarkable. Her mood stabilized, and even her chronic shoulder pain, known as frozen shoulder, began to dissipate and eventually disappeared. Waldman emphasizes the medical safety of LSD, citing its extremely low risk of overdose compared to common over-the-counter medications like acetaminophen. Furthermore, LSD is non-addictive and has fewer side effects than many prescription drugs used for mood disorders.

Waldman’s experience challenges the stigma surrounding psychedelic drugs. Her aim is to encourage a broader conversation about their potential benefits, especially in treating mood disorders and improving mental well-being. Her journey from a place of deep despair to newfound optimism demonstrates that unconventional approaches can lead to positive outcomes.

As Waldman explores alternative methods to maintain her emotional balance, she is not fixated on microdosing alone. She now incorporates nootropics, supplements believed to enhance cognitive function, and practices dialectical behavior therapy to manage her emotions. She remains open to various approaches and is determined to find a path that works for her.

In conclusion, Ayelet Waldman’s story is a testament to the potential benefits of microdosing LSD and the importance of challenging preconceived notions about psychedelics. Her journey towards emotional stability, improved relationships, and overall well-being serves as a beacon of hope for those seeking alternative solutions to mood disorders.

Source: https://www.newyorker.com/culture/persons-of-interest/how-ayelet-waldman-found-a-calmer-life-on-tiny-doses-of-lsd

The post Ayelet Waldman’s Positive Journey with Microdosing LSD appeared first on MicrodowingWordWide.com.

Microdosing Mushrooms for Mental Wellness: New Study Shows Promise for Improved Mood and Reduced Stress

Alex Askerka — Sat, 13 Jan 2024 15:00:00 +0000

In the ongoing dialogue surrounding alternative approaches to mental health, psilocybin microdosing has emerged as a captivating topic. Now, a new study published in December 2023 in Nature Scientific Reports adds compelling evidence to the potential benefits of this practice. Following nearly 1,200 people for a month, the study found significant improvements in mood and mental health among those who microdose psilocybin compared to a control group.

What is Microdosing Psilocybin?

Microdosing involves consuming minute amounts of psilocybin, the psychoactive compound found in “magic mushrooms,” insufficient to induce the full psychedelic experience. The typical dose is less than one-tenth of what would be considered recreational, often measured in micrograms. Proponents claim it fosters subtle but noticeable positive changes in mood, focus, and creativity.

The New Study: Promising Results Across the Board

The recent study compared 953 individuals who microdose psilocybin with 180 control participants who did not. Participants self-reported their mental health, mood, and cognitive function at the beginning and end of the month-long study period. Researchers observed:

Improved mood: Microdosers reported feeling happier, more energetic, and more emotionally resilient compared to the control group.
Reduced symptoms of mental health concerns: Those who microdosed psilocybin reported improvements in depression, PTSD, anxiety, and stress, regardless of whether they had previously diagnosed conditions.
Consistency across demographics: Positive effects were observed across genders, ages, and backgrounds, suggesting broad applicability of microdosing’s potential benefits.
Safe and well-tolerated: No significant adverse effects were reported by microdosers, further adding to the encouraging findings.

What These Findings Mean: A Path Forward

This study, while observational and requiring further controlled research, marks a significant milestone in understanding microdosing’s potential as a tool for mental wellness. The broad-ranging positive effects across diverse demographics point toward its promising future as a complementary approach to mental health support.

However, it’s important to emphasize that microdosing is not a magic bullet. While the latest research sheds light on its potential benefits, individual experiences may vary. Responsible practices include:

Consulting a healthcare professional: Seek guidance and ensure compatibility with existing medications or health conditions.
Starting low and slow: Begin with very small doses and adjust carefully under appropriate supervision.
Maintaining a mindful approach: Microdosing is not a quick fix; set realistic expectations and prioritize healthy well-being practices alongside it.

The Power of Individual Choice: Exploring Microdosing’s Potential

The growing body of research, coupled with this latest study’s encouraging findings, opens a door for further exploration of microdosing’s potential in supporting mental well-being. While more research is needed, the reported improvements in mood, mental health, and stress reduction among microdosers offer a promising avenue for individuals seeking alternative approaches to enhance their mental health journey.

Remember, taking control of your well-being is paramount. This research empowers individuals to explore and make informed decisions about their mental health care, paving the way for a more diverse and personalized approach to supporting optimal well-being.

The post Microdosing Mushrooms for Mental Wellness: New Study Shows Promise for Improved Mood and Reduced Stress appeared first on MicrodowingWordWide.com.